Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGEAN: Durvalumab for Resectable NSCLC
NCT03800134Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Pathological Complete Response at 15 weeks and Event-Free Survival at 5.5 years. Started Dec 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03800134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800134.